| Characteristic |
Circuit Group
(n=9) |
Interval Group
(n=11) |
| Age (years) |
71 (62-83) |
70 (66-87) |
| Sex (male/female) |
7/2 |
7/4 |
| Aetiology (ischemic/DCM) |
5/3 |
7/4 |
| NYHA Class II/III |
8/1 |
10/1 |
| Ejection Fraction (%) |
24 (15-40) |
34 (17-39) |
| Implantable device (CRT-D/CRT-P) |
3/2 |
3/2 |
| Atrial fibrillation |
2 |
4 |
| Resting heart rate (beats.min-1) |
66 (56-85) |
70 (40-86) |
| Systolic blood pressure (mmHg) |
107 (95-150) |
121 (92-154) |
| Diastolic blood pressure (mmHg) |
67 (54-98) |
75 (51-95) |
| Medication: |
|
|
| α blocker |
1 |
0 |
| Angiotensin converting enzyme inhibitor |
5 |
6 |
| Aldosterone antagonist |
0 |
1 |
| Angiotensin II receptor blocker |
4 |
5 |
| Anti-arrhythmic (amiodorone/digoxin) |
2/3 |
2/1 |
| β-blocker |
8 |
10 |
| Calcium channel blocker |
1 |
0 |
| Diuretic |
5 |
9 |
| Potassium channel activator |
0 |
1 |
| Statin |
6 |
8 |
NYHA: New York Heart Association; DCM: Dilated Cardiomyopathy; NYHA:
New York Heart Association; CRT-D: Cardiac Resynchronization Therapy With
Defibrillator; CRT-P: Cardiac Resynchronization Therapy With Pacing